Danaher’s recent decision to combine two of its companies—Cytiva and Pall Life Sciences—into a biotechnology group was designed to create one entity that covers the bioprocessing workflow from cell culture through drug products. As explained by Emmanuel Ligner, Danaher group executive, president, and CEO of Cytiva, “Pall and Cytiva will come together to provide our customers leading support to bring life-changing therapies to market faster and more efficiently.”
Both Cytiva and Pall offer a range of bioprocessing-related capabilities. Cytiva supports a variety of cell-culture steps—including cell expansion, production, and capture—plus polishing and even filling steps. Pall adds capabilities in culture clarification and viral inactivation, as well viral filtration, formulation and sterile filtration, and bulk filling.
For 2021, Danaher noted that Cytiva and Pall generated revenues of $6 billion and $2.5 billion, respectively. Beyond combining those revenues, merging Cytiva and Pall gives Danaher’s biotechnology group 36 global manufacturing sites, more than 20 R&D innovation centers, and sales in 110 countries. Adding to that, Danaher reported that more than $1.5 billion will be invested in this biotechnology group by 2025 for further expansion.
As Linger concludes: “The combined company will have a broad and differentiated portfolio, superior global scale and reach, and the industry’s largest and most trusted commercial and service organization.”
